Clinical Trials
11 trialsNCT00469209 2020-09-24
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00006021 2016-12-15
Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
University of Miami
Phase 1/2 Completed
NCT00504101 2016-12-15
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
University of Miami
Phase 1 Withdrawn
NCT00201695 2015-06-10
Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00590603 2014-01-08
AAV
Duke University
Phase 1 Terminated
NCT00003395 2013-06-25
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00258245 2013-04-29
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT00661544 2013-03-04
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00006220 2013-02-06
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
Washington University School of Medicine
Phase 1/2 Terminated
NCT00227682 2012-05-28
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00193544 2009-01-23
Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Completed